Abstract:Developing effective anti-fibrotic therapies for heart diseases holds the potential to address unmet needs in several cardiac conditions, including heart failure with preserved ejection fraction, hypertrophic cardiomyopathy, and cardiotoxicity induced by cancer therapy. The inhibition of the primary fibrotic regulator, transforming growth factor (TGF) β, represents an efficient strategy for mitigating fibrosis in preclinical models. However, translating these findings into clinical benefits faces challenges due to potential adverse effects stemming from TGF-β's physiological actions in inflammation and tissue homeostasis. Various strategies exist for inhibiting TGF-β, each associated with a distinct risk of adverse effects. Targeting TGF-β directly or through its signaling pathway proves efficient in reducing fibrosis. However, direct TGF-β blockade may lead to uncontrolled inflammation, especially following myocardial infarction, while interference with the signaling pathway may compromise structural integrity, resulting in issues like insufficient wound healing or ventricular dilatation. Influencing TGF-β activity through interacting signaling pathways, for instance by inhibitors of the renin–angiotensin–aldosterone-system, is insufficiently potent in reducing fibrosis. Targeting activators of latent TGF-β, including ADAMTS enzymes, thrombospondin, and integrins, emerges as a potentially safer strategy to reduce TGF-β-induced fibrosis but it requires the identification of appropriate targets. Encouragement is drawn from promising agents developed for fibrosis in other organs, fueling hope for similar breakthroughs in treating cardiac fibrosis. Such advances depend on overcoming obstacles for the implementation of anti-fibrotic strategies in patients with heart disease, including fibrosis quantification. In this review, insights garnered from interventional and mechanistic studies, obtained through a non-systemic search spanning preclinical and clinical evidence, are summarized to pinpoint the most promising targets for further exploration and development.

Targeting Asporin in Lung Fibrosis: A New Approach to an Old Concept

The Potentially Therapeutic Role of EPAC in Curbing the Process of Idiopathic Pulmonary Fibrosis Via Differential Cellular Pathways

Asporin Promotes TGF-β–induced Lung Myofibroblast Differentiation by Facilitating Rab11-Dependent Recycling of TβRI

Therapeutic Targeting of Src Kinase and Myofibroblast Activation in Pulmonary Fibrosis

Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis

Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases

TGF{beta} drives fibrotic remodeling via modulation of homeostatic and pathological fibroblast populations in a murine model of pulmonary fibrosis

Targeting TGF-β signal transduction for fibrosis and cancer therapy

Transforming growth factor-β signaling: From tissue fibrosis to therapeutic opportunities

Selective Targeting of TGF-β Activation to Treat Fibroinflammatory Airway Disease

Hitting the Target! Challenges and Opportunities for TGF-β Inhibition for the Treatment of Cardiac fibrosis

Simultaneously Targeting Myofibroblast Contractility and Extracellular Matrix Cross-Linking as a Therapeutic Concept in Airway Fibrosis

Astaxanthin attenuates pulmonary fibrosis through lncITPF and mitochondria‐mediated signal pathways

TGF-β changes cyto/mito-ribosome balance to target respiratory chain complex V biogenesis in pulmonary fibrosis therapy

Transforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts

Asarinin attenuates bleomycin-induced pulmonary fibrosis by activating PPARγ

Thromboxane-Prostanoid Receptor Signaling Drives Persistent Fibroblast Activation in Pulmonary Fibrosis.

Targeting TGR5 Ameliorates Pulmonary Fibrosis by Regulating TGF-β1 Associated Signaling Pathways

Drugs targeting CTGF in the treatment of pulmonary fibrosis

Interference with connective tissue growth factor attenuated fibroblast-to-myofibroblast transition and pulmonary fibrosis

Transforming Growth Factor-β Pathway and Molecular Treatment of Liver Fibrosis